secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001558370-23-002942
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte reports preliminary FY2022 revenue $44.3M (+31% YoY); guides 2023 growth 21-26%
--------------------------------------------------------------------------------

- FY2022 total revenue ~$44.3M, up 31% from $33.9M in 2021; Q4 revenue ~$12.4M, up 22%.
- Installed base >600 instruments (vs >500 end 2021); 18 SPL partnerships at year-end, 19 after Jan 2023.
- 2023 guidance: total revenue growth 21-26%, core growth 20-25%, SPL program-related revenue ~$6M.
- Potential pre-commercial milestones under SPLs >$1.55B; 16 licensed clinical programs in clinic.
- SPL program-related revenue in FY2022 was $4.6M vs $2.5M in 2021; Q4 included $1.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023002942/0001558370-23-002942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837023002942/mxct-20230306x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer